{"protocolSection": {"identificationModule": {"nctId": "NCT00809926", "orgStudyIdInfo": {"id": "CSPV100AUS01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension", "officialTitle": "An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension", "acronym": "VANTAGE"}, "statusModule": {"statusVerifiedDate": "2011-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-01"}, "primaryCompletionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-12-16", "studyFirstSubmitQcDate": "2008-12-16", "studyFirstPostDateStruct": {"date": "2008-12-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-10", "resultsFirstSubmitQcDate": "2011-03-31", "resultsFirstPostDateStruct": {"date": "2011-05-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-03-31", "lastUpdatePostDateStruct": {"date": "2011-05-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension."}, "conditionsModule": {"conditions": ["Stage 2 Hypertension"], "keywords": ["Hypertension, aliskiren and valsartan"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 451, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan/aliskiren", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan/aliskiren"]}, {"label": "Valsartan", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Valsartan"]}], "interventions": [{"type": "DRUG", "name": "Valsartan/aliskiren", "description": "Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks", "armGroupLabels": ["Valsartan/aliskiren"]}, {"type": "DRUG", "name": "Valsartan", "description": "Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks", "armGroupLabels": ["Valsartan"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8", "description": "To compare the change from baseline in MSSBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "timeFrame": "Baseline to Week 8"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8", "description": "To compare the change in MSDBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan (160 mg, 320 mg) treatment regimen in patients with Stage 2 Hypertension.", "timeFrame": "Baseline to Week 8"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control (Defined as Patients Achieving a MSSBP <140 mmHg and MSDBP <90 mmHg) at Week 8", "description": "To evaluate the percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP \\<140 mmHg and MSDBP \\<90 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "timeFrame": "At Week 8"}, {"measure": "Percentage of Responders (Defined as Patients With MSSBP <140 mmHg or a Decrease From Baseline \u226520 mmHg) at Week 8", "description": "To compare the percentage of responders (defined as patients with MSSBP \\<140 mmHg or a decrease from baseline \u226520 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "timeFrame": "At Week 8"}, {"measure": "Mean Change From Baseline in Plasma Renin Activity (PRA) at Week 8", "description": "To assess the change from baseline in PRA after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "timeFrame": "Baseline to Week 8"}, {"measure": "Mean Change From Baseline in Plasma Renin Concentration (PRC) at Week 8", "description": "To assess the change from baseline in PRC after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "timeFrame": "Baseline to Week 8"}], "otherOutcomes": [{"measure": "Completers Analysis for Change From Baseline in MSSBP at Week 8", "description": "To evaluate the change from baseline in MSSBP (mmHg) at Week 8; primary efficacy variable at primary time point in ITT population - patients who completed the double-blind treatment period.", "timeFrame": "Baseline to week 8"}, {"measure": "Longitudinal Repeated Measure Analysis for Change in MSSBP From Baseline Through Week 8", "description": "To evaluate the change from baseline in MSSBP (mmHg) after 8 weeks; primary efficacy variable (ITT population) using Longitudinal analysis (A repeated measures analysis where assessments over time are considered , as opposed to looking at a single point in time.)", "timeFrame": "Baseline through week 8"}, {"measure": "Change From Baseline in Mean Ambulatory Systolic Blood Pressure (MASBP).", "description": "To evaluate 24-hour ambulatory systolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.", "timeFrame": "Baseline to week 8"}, {"measure": "Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (MADBP)", "description": "To evaluate 24-hour ambulatory diastolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.", "timeFrame": "Baseline to week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.\n* Men or women 18 years and older.\n* Patients with Stage 2 systolic hypertension; defined as having a MSSBP \u2265160 mmHg and \\<180 mmHg at Visit 5 (randomization).\n\nExclusion Criteria:\n\n* Use of aliskiren or participation in a clinical trial that had aliskiren as treatment within 30 days of Visit 1.\n* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\\>5 mIU/ml).\n* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \\>40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception (implantable, patch, oral), and double-barrier methods. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.\n* Severe hypertension (an office cuff MSDBP \u2265110 mmHg and/or MSSBP \u2265180 mmHg).\n* Refractory hypertension, defined as unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg).\n* Patients treated with more than 3 antihypertensive medications (each component of a combination drug counts individually).\n* History or evidence of a secondary form of hypertension.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Sites in USA", "city": "East Hanover", "state": "New Jersey", "zip": "07936", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}]}, "referencesModule": {"references": [{"pmid": "22321963", "type": "DERIVED", "citation": "Flack JM, Yadao AM, Purkayastha D, Samuel R, White WB. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension. J Am Soc Hypertens. 2012 Mar-Apr;6(2):142-51. doi: 10.1016/j.jash.2011.11.004. Epub 2012 Feb 9."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "FG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "232"}, {"groupId": "FG001", "numSubjects": "219"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "201"}, {"groupId": "FG001", "numSubjects": "196"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "23"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Administrative Problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "BG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "232"}, {"groupId": "BG001", "value": "219"}, {"groupId": "BG002", "value": "451"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.5", "spread": "11.1"}, {"groupId": "BG001", "value": "56.7", "spread": "11.0"}, {"groupId": "BG002", "value": "57.1", "spread": "11.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "116"}, {"groupId": "BG002", "value": "223"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "125"}, {"groupId": "BG001", "value": "103"}, {"groupId": "BG002", "value": "228"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8", "description": "To compare the change from baseline in MSSBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "populationDescription": "Intent-to-treat (ITT) population consisted of all randomized patients who received at least 1 dose of study drug and had valid baseline and 1 valid post-baseline assessment of an efficacy variable. The last-observation-carried-forward (LOCF) method was used for replacing the missing values of the post-baseline assessments for ITT analysis at wk 8.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.8", "spread": "4.54"}, {"groupId": "OG001", "value": "166.2", "spread": "5.23"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "142.3", "spread": "17.01"}, {"groupId": "OG001", "value": "145.6", "spread": "17.55"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.5", "spread": "16.04"}, {"groupId": "OG001", "value": "-20.6", "spread": "16.25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.295", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-1.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.61", "ciUpperLimit": "1.40"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8", "description": "To compare the change in MSDBP after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan (160 mg, 320 mg) treatment regimen in patients with Stage 2 Hypertension.", "populationDescription": "Intent-to-treat (ITT) population consisted of all randomized patients who received at least 1 dose of study drug and had valid baseline and 1 valid post-baseline assessment of an efficacy variable. The last-observation-carried-forward (LOCF) method was used for replacing the missing values of the post-baseline assessments for ITT analysis at wk 8.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.9", "spread": "8.22"}, {"groupId": "OG001", "value": "94.8", "spread": "8.68"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "85.7", "spread": "10.94"}, {"groupId": "OG001", "value": "86.4", "spread": "10.34"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.2", "spread": "9.77"}, {"groupId": "OG001", "value": "-8.3", "spread": "9.49"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.790", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.93", "ciUpperLimit": "1.47"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control (Defined as Patients Achieving a MSSBP <140 mmHg and MSDBP <90 mmHg) at Week 8", "description": "To evaluate the percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP \\<140 mmHg and MSDBP \\<90 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had valid baseline and at least one valid post-baseline assessment of an efficacy variable.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "At Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.3"}, {"groupId": "OG001", "value": "36.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.101", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference", "paramValue": "8.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.56", "ciUpperLimit": "17.67"}]}, {"type": "SECONDARY", "title": "Percentage of Responders (Defined as Patients With MSSBP <140 mmHg or a Decrease From Baseline \u226520 mmHg) at Week 8", "description": "To compare the percentage of responders (defined as patients with MSSBP \\<140 mmHg or a decrease from baseline \u226520 mmHg) at week 8 following treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had valid baseline and at least one valid post-baseline assessment of an efficacy variable.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of responders", "timeFrame": "At Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "64.7"}, {"groupId": "OG001", "value": "53.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.018", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Difference", "paramValue": "11.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.00", "ciUpperLimit": "21.33"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Plasma Renin Activity (PRA) at Week 8", "description": "To assess the change from baseline in PRA after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had valid baseline and at least one valid post-baseline assessment of an efficacy variable.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL/h", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.992", "spread": "1.290"}, {"groupId": "OG001", "value": "0.831", "spread": "0.854"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.436", "spread": "0.659"}, {"groupId": "OG001", "value": "2.450", "spread": "3.73"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.540", "spread": "1.285"}, {"groupId": "OG001", "value": "1.577", "spread": "3.528"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Plasma Renin Concentration (PRC) at Week 8", "description": "To assess the change from baseline in PRC after 8 weeks of treatment with a valsartan and aliskiren treatment regimen (160/150 mg, 320/300 mg) versus a valsartan treatment regimen (160 mg, 320 mg) in patients with Stage 2 Hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had valid baseline and at least one valid post-baseline assessment of an efficacy variable.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "Baseline to Week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.286", "spread": "10.893"}, {"groupId": "OG001", "value": "8.065", "spread": "14.932"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "142.833", "spread": "293.228"}, {"groupId": "OG001", "value": "20.089", "spread": "31.771"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "135.515", "spread": "296.758"}, {"groupId": "OG001", "value": "11.988", "spread": "32.679"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Completers Analysis for Change From Baseline in MSSBP at Week 8", "description": "To evaluate the change from baseline in MSSBP (mmHg) at Week 8; primary efficacy variable at primary time point in ITT population - patients who completed the double-blind treatment period.", "populationDescription": "The analysis included ITT patients who completed the double-blind treatment period \\[those patients with a final observation at week 8, also known as observed cases (OC)\\]. This analysis differed from the ITT-LOCF analysis, in that it did not include patients who discontinued from the trial prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "196"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.8", "spread": "4.54"}, {"groupId": "OG001", "value": "166.2", "spread": "5.23"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.9", "spread": "15.74"}, {"groupId": "OG001", "value": "145.9", "spread": "16.89"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.0", "spread": "14.70"}, {"groupId": "OG001", "value": "-20.3", "spread": "15.49"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.028", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-3.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.34", "ciUpperLimit": "-0.37"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Longitudinal Repeated Measure Analysis for Change in MSSBP From Baseline Through Week 8", "description": "To evaluate the change from baseline in MSSBP (mmHg) after 8 weeks; primary efficacy variable (ITT population) using Longitudinal analysis (A repeated measures analysis where assessments over time are considered , as opposed to looking at a single point in time.)", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had valid baseline and at least one valid post-baseline assessment of an efficacy variable.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline through week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "230"}, {"groupId": "OG001", "value": "217"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-23.2", "spread": "1.04"}, {"groupId": "OG001", "value": "-20.1", "spread": "1.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.040", "statisticalMethod": "GENMOD", "statisticalComment": "Based on a generalized estimating equations using SAS procedure GENMOD.", "paramType": "Least Square Mean Difference", "paramValue": "-3.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.02", "ciUpperLimit": "-0.14"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Mean Ambulatory Systolic Blood Pressure (MASBP).", "description": "To evaluate 24-hour ambulatory systolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.", "populationDescription": "Patients who were willing to participate in the Ambulatory Blood Pressure Monitoring (ABPM) substudy and who met the study inclusion and exclusion criteria for randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "146.1", "spread": "9.14"}, {"groupId": "OG001", "value": "143.5", "spread": "14.10"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.3", "spread": "13.41"}, {"groupId": "OG001", "value": "137.6", "spread": "17.11"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.8", "spread": "11.42"}, {"groupId": "OG001", "value": "-6.0", "spread": "13.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-8.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.38", "ciUpperLimit": "-2.93"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (MADBP)", "description": "To evaluate 24-hour ambulatory diastolic blood pressure measurements in a subset of patients after 8 weeks of treatment with the combination of valsartan and aliskiren versus valsartan monotherapy in patients with stage 2 hypertension.", "populationDescription": "Patients who were willing to participate in the ABPM substudy and who met the study inclusion and exclusion criteria for randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to week 8", "groups": [{"id": "OG000", "title": "Valsartan/Aliskiren", "description": "For the first 2 weeks patients received Valsartan/aliskiren (160/150mg). For the remaining 6 weeks, all patients received Valsartan/aliskiren 320/300mg (forced titration)."}, {"id": "OG001", "title": "Valsartan", "description": "For the first 2 weeks patients received Valsartan 160 mg. For the remaining 6 weeks, all patients received Valsartan 320 mg (forced titration)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.9", "spread": "7.28"}, {"groupId": "OG001", "value": "85.7", "spread": "9.26"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.2", "spread": "9.44"}, {"groupId": "OG001", "value": "81.7", "spread": "10.11"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.7", "spread": "7.02"}, {"groupId": "OG001", "value": "-4.0", "spread": "8.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.006", "statisticalMethod": "ANCOVA", "paramType": "Least Square Mean Difference", "paramValue": "-4.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.37", "ciUpperLimit": "-1.42"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline through week 8", "eventGroups": [{"id": "EG000", "title": "Valsartan/ Aliskiren", "description": "Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks", "seriousNumAffected": 5, "seriousNumAtRisk": 232, "otherNumAffected": 14, "otherNumAtRisk": 232}, {"id": "EG001", "title": "Valsartan", "description": "Valsartan (160mg) for 2weeks followed by forced titration toValsartan (320mg) for the remaining 6 weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 219, "otherNumAffected": 15, "otherNumAtRisk": 219}], "seriousEvents": [{"term": "Lymphocytosis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 219}]}, {"term": "Anaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}, {"term": "Hemiparesis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}, {"term": "Confusional state", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}, {"term": "Conversion disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 219}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 232}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 219}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}